Prime Medicine Announces First Patient Dosed In Phase 1/2 Trial Of PM577a In Wilson Disease; Receives FDA Rare Pediatric Disease Designation
Share
Why It Matters
Prime Medicine started testing a new treatment for Wilson disease, a rare condition. The FDA gave it special status, which could help speed up the approval process.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.